Background: The pleiotropic cytokine interleukin-6 mediates its multiple effects at the cell level through a multimeric receptor consisting of a binding protein
INTRODUCTION
Infection or trauma inflicted on an organism is followed by an immediate local and systemic response aimed at halting tissue destruction, removing the infecting organisms or tissue, and restoring the physiologic balance. One of the most potent mechanisms involved in this reac-tion is the release of cytokines into the circulation in an ordered and precise manner, with interleukin-6 in combination with others playing a very important role during such acute pathologic conditions. IL-6 has been shown more specifically to regulate the acute phase reaction, the immune response, and many other crucial components of the homeostatic response (1, 2) . IL-6 acts at the surface of cells through a specific receptor, gp8O or a chain, which binds the IL-6 ligand with low affinity. After the formation of this IL-6/IL-6R complex, a third component, gpl30 or 13 chain, is necessary to transduce the signal to the cell. This last step involves formation of a high-affinity interaction between IL-6 and the chains of the receptor. Recent data seem to indicate formation of a hexameric complex of two molecules each of IL-6, a chain, and X3 chain (3, 4) .
The short intracytoplasmic domain of gp8O has been shown not to be needed to trigger a cellular IL-6-mediated response. Indeed, a recombinant protein consisting of the extracellular domain of gp8O, gp55-soluble IL-6R (sIL-6R), is still able to bind IL-6, and this complex, IL-6/sIL-6R, by interacting with gpl 30, induces an intracellular signal (5, 6 ). Although we possess much information on the possible roles of sIL-6R in vitro, its precise role in vivo remains unclear. An effect on the central nervous system has been suggested (7) (8) (9) (10) (11) (12) (13) . Availability of immunoassays to measure sIL-6R reveals the relatively high circulating concentrations of this protein either under normal conditions or during pathologic states (14) (15) (16) . More recently, severe sepsis and fatal outcome have been associated with elevated levels of sIL-6R (17) .
Methods to investigate the physiologic role of a protein depend often on availability of the molecule under consideration in recombinant purified form. In addition to injecting recombinant material to an animal, a novel approach to induce a transient increase in the level of a defined protein is to generate a vector carrying the gene encoding for it. Recent data from our lab and others have proven the potency of recombinant adenoviruses to deliver cytokine genes to various tissues and thereby induce sustained increases in circulating levels of particular cytokines (18, 26, (39) (40) (41) .
To investigate the physiologic role of sIL-6R in an animal model, we constructed a replication-deficient adenovirus vector carrying the gene encoding the extracellular domain of IL-6R (Ad5.rsIL-6R). We describe the molecular strategy we used as well as the characterization of the protein synthesized by this recombinant virus in different cell lines. As previously shown with other adenoviruses expressing cytokines, Ad5.rsIL-6R-infected cells secrete high amounts of sIL-6R in vitro over a period of at least 10 days. The recombinant protein is biologically active, and intratracheal administration of the recombinant vector to rats induces the production of sIL-6R within lung tissue over a period of at least 10 days, as detected in bronchoalveolar lavage (BAL) fluid.
MATERIALS AND METHODS
Generation of cDNA Encoding Rat-Soluble IL-6R (p55) Total RNA was prepared from primary rat hepatocytes as previously described (19) . A reverse transcription reaction was conducted according to manufacturer protocol using poly-dT as primer and M-MLV reverse transcriptase (GIBCO BRL, Gaithersburg, MD). The cDNA obtained was amplified by polymerase chain reaction using a set of primers (Mobix, McMaster University) and Vent DNA and RNA were obtained from 293 cells as previously described and run on Southern and Northern blot according to previously described protocols (22) . The rat sIL-6R probe used was the Styl fragment corresponding to the extracellular domain (63-931 bp).
Animals
Sprague-Dawley rats were injected intratracheally as previously described (21) . In brief, rats were anesthesized, incised at the trachea level, and 300 ,ll of virus diluted to the proper concentration in sterile PBS were slowly instilled with a 21 -G needle. At different time points, rats were euthanized and the lungs lavaged (BAL) with 3 ml of sterile PBS. (37) .
Antibody to Rat sIL-6R
Specific antibody to rat sIL-6R was generated by initial immunization of rabbits with 109 plaqueforming units (pfu) of recombinant adenovirus expressing rat sIL-6R. One month later, rabbits were boosted with 20 ,ug of purified rat sIL-6R derived from a baculovirus expression system as previously described (42) were collected 5 days after infection, centrifuged, and run on a Western blot. Proteins were revealed with the primary antibody directed against rat sIL-6R. Figure 3 shows clearly a specific band migrating around 55 kD, indicating the presence of sIL-6R only in the supernatants of cells infected with Ad5.sIL-6R and not in those infected with the control virus.
Kinetics of Production of Rat sIL-6R in
Rodent and Human Cells Infected with Ad5.rsIL-6R Since adenoviruses do not integrate into the genome of host cells and stay as an episomal form of DNA, it is important to define the kinetics of protein expression, especially the maximal time of recombinant protein production. Rat or human lung fibroblasts and hepatoma cells were infected with Ad5.rsIL-6R at a MOI of 10 at Day 0 and the medium was collected and replaced every day for 9 days. Depending on the cell line and the species, the kinetics of production were quite different (Fig. 4) Fig. 4 (Fig. 6 ). 
DISCUSSION
The soluble extracellular domain of the gp8O IL-6 receptor (sIL-6R), a 45-55 kD glycoprotein, has been detected at significant levels in biologic fluids such as urine, cerebrospinal fluids, and synovial fluids (17, 43, 44 (23, 24) . RNA isolation from hepatoma cells of two different species, rat and human, demonstrate the difference of activity of the promoter, depending on the host (25) . Other data from our lab indicate that the pACCMV promoter works best in human cells but is also active in rodent cells (V. Thibault et al., unpublished data). By integrating the bands on Northern and Western blots we could estimate the pACCMV promoter activity in rodent hepatoma to be around seven times less active than in human cells. In fibroblasts, the difference is even greater. Activity of the promoter is therefore highly dependent on the type of cells studied even though its activity translates into high recombinant protein production. At the peak of expression, human fibroblasts release a maximum rat sIL-6R of 13 ,g/ml/105 cells/24 hr, whereas rodent hepatoma cells peak at 400 ng/ml/ 105 cells/24 hr. This amount of protein produced is in the same range as what we and others have reported earlier with recombinant adenoviruses expressing other cytokines or proteins (26) (27) (28) . The kinetics of in vitro protein production is also dependent on cell type, with steady production from hepatoma cells from Day 1 or 2 and a peak expression at Day 5 for lung fibroblasts.
Vaccination of rabbits with 109 pfu i.p. of adenovirus vector expressing rat sIL-6R and several boosts with baculovirus-purified recombinant material generated specific antibodies against rat sIL-6R. An ELISA was established on the basis of an antibody capture assay. The range of linearity was between 10 to 500 ng/ml. We could not detect (by ELISA or Western blot) sIL-6R in any of the control virus-infected cells or BAL from control virus-infected animals. Recombinant rat IL-6 did not interact with the antibody. To our knowledge, this is the first ELISA to measure rat sIL-6R.
We and others have previously characterized the distribution of adenovirus-mediated gene delivery to the lungs (21, 29, 30, 40, 41) . The primary cell infected is the bronchial epithelial cell, but all major cell types within the airways are infectable, and access to the lung space allows assessment of the production kinetics of the transgene through bronchoalveolar lavage. Previous experiments in our lab have shown transient expression of the transgene for at least 5 We did not measure IL-6 in these animals, as we have previously shown that the presence of rat sIL-6R in samples markedly affects the B9 hybridoma cell activity assay for rat IL-6 (42). We currently do not possess an ELISA for rat IL-6, but this will be needed to determine the effect of receptor overexpression on IL-6 levels.
We have previously shown that purified recombinant rat sIL-6R could confer responsiveness of human hepatoma cells (HepG2) to rat IL-6, this system being the most convenient to test for rat sIL-6R activity (42) . Ad5.rsIL-6R infection of HepG2 cells did not modify basal or human IL-6-stimulated acute phase protein production, but stimulation of AdS.rsIL-6R-infected HepG2 with rat IL-6 induced a strong acute phase protein response not seen in cells infected with control virus (Ad5.E1.LacZ). We were able to induce a 3-fold increase in a-I antichymotrypsin production, a level of stimulation identical to the one induced by human IL-6 on HepG2 cells. The intensity of the response seen after infection with rat sIL-6R producing vector is very similar to that seen using a combination of recombinant rat sIL-6R and rat IL-6 (42 
